Eradication of HIV: Current Challenges and New Directions

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2008 Nov 6

PMID 18984648

Citations 36

Authors

Matthew D Marsden

Jerome A Zack

Affiliations

Soon will be listed here.

Abstract

Highly active antiretroviral therapy (HAART) can potently suppress human immunodeficiency virus (HIV) replication and prevent progression to AIDS. However, HAART does not cure infected patients. Instead, HIV persists in latently infected CD4+ T cells and various cryptic cellular reservoirs. Hence, under current therapy regimens, patients must continue taking HAART for the remainder of their lives. Eliminating residual replication-competent virus is critical if eradication of HIV is to be achieved. While this challenge is formidable, we describe here a number of innovative approaches intended to further deplete HIV in HAART-treated patients. New antiretroviral drugs that target different viral proteins and stages of the virus life cycle, compounds that enhance anti-HIV immune responses and novel gene therapy approaches may each play a role in improving long-term suppression of the virus. Moreover, methods for more specifically and efficiently inducing HIV from latency and eliminating the newly activated host cells are also under development.

Citing Articles

Novel Nanotechnology-Based Approaches for Targeting HIV Reservoirs.

Fotooh Abadi L, Damiri F, Zehravi M, Joshi R, Pai R, Berrada M Polymers (Basel). 2022; 14(15).

PMID: 35956604 PMC: 9370744. DOI: 10.3390/polym14153090.

Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.

Wang X, Xu H Viruses. 2021; 13(2).

PMID: 33670027 PMC: 7926539. DOI: 10.3390/v13020335.

Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption.

Wu Y, Pinkevych M, Xu Z, Keele B, Davenport M, Cromer D Proc Biol Sci. 2020; 287(1933):20200354.

PMID: 32811309 PMC: 7482276. DOI: 10.1098/rspb.2020.0354.

Phyloanatomic characterization of the distinct T cell and monocyte contributions to the peripheral blood HIV population within the host.

RifeMagalis B, Strickland S, Shank S, Autissier P, Schuetz A, Sithinamsuwan P Virus Evol. 2020; 6(1):veaa005.

PMID: 32355568 PMC: 7185683. DOI: 10.1093/ve/veaa005.

Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery.

Grande F, Ioele G, Occhiuzzi M, De Luca M, Mazzotta E, Ragno G Pharmaceutics. 2019; 11(5).

PMID: 31035595 PMC: 6572254. DOI: 10.3390/pharmaceutics11050197.

References

Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H . Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007; 13(10):1241-7. DOI: 10.1038/nm1639. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron P, Lewin S . CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007; 110(13):4161-4. DOI: 10.1182/blood-2007-06-097907. View

Murray J, Emery S, Kelleher A, Law M, Chen J, Hazuda D . Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007; 21(17):2315-21. DOI: 10.1097/QAD.0b013e3282f12377. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

Lowry W, Richter L, Yachechko R, Pyle A, Tchieu J, Sridharan R . Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. 2008; 105(8):2883-8. PMC: 2268554. DOI: 10.1073/pnas.0711983105. View

Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna G, Brun S . Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008; 105(10):3879-84. PMC: 2268833. DOI: 10.1073/pnas.0800050105. View

Wender P, Kee J, Warrington J . Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science. 2008; 320(5876):649-52. PMC: 2704988. DOI: 10.1126/science.1154690. View

10.

Marsden M, Xu J, Hamer D, Zack J . Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses. 2008; 24(11):1399-404. PMC: 2928488. DOI: 10.1089/aid.2008.0082. View

11.

Chun T, Davey Jr R, Engel D, Lane H, Fauci A . Re-emergence of HIV after stopping therapy. Nature. 1999; 401(6756):874-5. DOI: 10.1038/44755. View

12.

Davey Jr R, Bhat N, Yoder C, Chun T, Metcalf J, Dewar R . HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999; 96(26):15109-14. PMC: 24781. DOI: 10.1073/pnas.96.26.15109. View

13.

Sharkey M, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan J . Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 1999; 6(1):76-81. PMC: 9513718. DOI: 10.1038/71569. View

14.

Kulkosky J, Culnan D, Roman J, Dornadula G, Schnell M, Boyd M . Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001; 98(10):3006-15. DOI: 10.1182/blood.v98.10.3006. View

15.

Scripture-Adams D, Brooks D, Korin Y, Zack J . Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002; 76(24):13077-82. PMC: 136703. DOI: 10.1128/jvi.76.24.13077-13082.2002. View

16.

Brooks D, Hamer D, Arlen P, Gao L, Bristol G, Kitchen C . Molecular characterization, reactivation, and depletion of latent HIV. Immunity. 2003; 19(3):413-23. DOI: 10.1016/s1074-7613(03)00236-x. View

17.

Li F, Goila-Gaur R, Salzwedel K, Kilgore N, Reddick M, Matallana C . PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003; 100(23):13555-60. PMC: 263852. DOI: 10.1073/pnas.2234683100. View

18.

Amado R, Mitsuyasu R, Rosenblatt J, Ngok F, Bakker A, Cole S . Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004; 15(3):251-62. DOI: 10.1089/104303404322886101. View

19.

Chun T, Carruth L, Finzi D, Shen X, DiGiuseppe J, Taylor H . Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629):183-8. DOI: 10.1038/387183a0. View

20.

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View